The treatment success rate for patients with multidrug-resistant tuberculosis (MDR-TB) in Brazil is forecasted to stabilize at 60% for 2024 and 2025, with a slight increase to 61% from 2026 to 2028. As of 2023, the rate was similar, suggesting minimal improvement over the forecast period. The year-on-year variation remains negligible, indicating a flat trend. The projected compound annual growth rate (CAGR) over five years is minimal, showcasing a slow-paced progress.
Future trends to watch for include advancements in medical treatments and policy interventions that could enhance treatment success rates. Emerging technologies and improved healthcare infrastructure might play significant roles in shaping positive outcomes.
